- Home/In The News/Blog
9
June2015
category:
503b CompoundingOphthalmologists and Patients Demand Quality Compounded Drugs at Affordable Prices
Access to compounding medications critical for ophthalmologists, patients http://www.healio.com/ophthalmology/practice-management/news/print/ocular-surgery-news/%7Bebef4371-1c0c-460d-b3cb-6e8d524915e2%7D/access-to-compounded-medications-critical-for-ophthalmologists-patients?page=1 Ocular Surgery News U.S. Edition, May 25, 2015 Richard L. Lindstrom, MD The decisions the FDA makes are critical to ophthalmologists and patients, especially in the anti-VEGF category. As I mentioned above, no generic anti-VEGF injectables are available. Lucentis (ranibizumab, Genentech) and Eylea, branded and patent-protected […]
read more18
May2015
category:
503b CompoundingNew Poll Finds Strong Support For Effective FDA Regulation of Compounding Pharmacies
WASHINGTON, SEPT. 18, 2013 — Voters Expect to Be Informed If They Are Prescribed A Drug Not Approved By the FDA As Congress considers legislation to address the oversight of compounding pharmacies, a new, independent survey released today highlights the large gap between voters’ expectations that the medications they receive are FDA-approved and loopholes in […]
read more29
September2014
category:
503b CompoundingClinigen Group plc Receives FDA’s First Ever Drug Shortage Assistance Award
URTON-ON-TRENT, England, Sep 29, 2014 (BUSINESS WIRE) — Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM:CLIN) the global specialty pharmaceutical company, today announces that it has received the first Drug Shortage Assistance Award from the US Food and Drug Administration (FDA)in recognition of its contribution in addressing a US shortage of Foscavir® (foscarnet sodium) injection. […]
read more